Israel - English - Ministry of Health

rafa laboratories ltd - sulpiride - capsules - sulpiride 50 mg - sulpiride - sulpiride - anti - dopaminergic agent for use in vertigo and prepsychotic states.

Australia - English - Department of Health (Therapeutic Goods Administration)

luminarie pty ltd - mefenamic acid, quantity: 250 mg - capsule, hard - excipient ingredients: lactose monohydrate; titanium dioxide; purified water; quinoline yellow; gelatin; sodium lauryl sulfate; brilliant scarlet 4r - treatment of primary dysmenorrhoea and primary menorrhagia.,short-term relief of mild to moderate pain such as dental pain and soft tissue pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - mefenamic acid, quantity: 250 mg - capsule, hard - excipient ingredients: lactose monohydrate; titanium dioxide; purified water; quinoline yellow; gelatin; sodium lauryl sulfate; brilliant scarlet 4r - treatment of primary dysmenorrhoea and primary menorrhagia.,short-term relief of mild to moderate pain such as dental pain and soft tissue pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - mefenamic acid, quantity: 250 mg - capsule, hard - excipient ingredients: lactose monohydrate; titanium dioxide; purified water; quinoline yellow; gelatin; sodium lauryl sulfate; brilliant scarlet 4r - treatment of primary dysmenorrhoea and primary menorrhagia.,short-term relief of mild to moderate pain such as dental pain and soft tissue pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - mefenamic acid, quantity: 250 mg - capsule, hard - excipient ingredients: gelatin; carbon black; iron oxide yellow; brilliant blue fcf; lactose monohydrate; titanium dioxide - treatment of primary dysmenorrhoea and primary menorrhoea. short-term relief of mild to moderate pain such as dental pain and soft tissue pain.

Australia - English - Department of Health (Therapeutic Goods Administration)

besins healthcare australia pty ltd - progesterone, quantity: 200 mg - capsule, soft - excipient ingredients: glycerol; lecithin; titanium dioxide; gelatin; purified water; sunflower oil - prometrium 100 mg and 200 mg, soft capsules are indicated for:,treatment of menstrual irregularities,- in women with menstrual abnormalities or secondary amenorrhoea due to normogonadotrophic amenorrhoea (see dosage and administration),hormone replacement therapy,- hormone replacement therapy ? adjunctive use with an oestrogen in postmenopausal women with an intact uterus

Australia - English - Department of Health (Therapeutic Goods Administration)

besins healthcare australia pty ltd - progesterone, quantity: 100 mg - capsule, soft - excipient ingredients: glycerol; lecithin; titanium dioxide; gelatin; purified water; sunflower oil - prometrium 100 mg and 200 mg, soft capsules are indicated for:,treatment of menstrual irregularities,- in women with menstrual abnormalities or secondary amenorrhoea due to normogonadotrophic amenorrhoea (see dosage and administration),hormone replacement therapy,- hormone replacement therapy ? adjunctive use with an oestrogen in postmenopausal women with an intact uterus

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - lenalidomide, quantity: 25 mg - capsule, hard - excipient ingredients: lactose; titanium dioxide; purified water; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm)- lenalidomide is indicated for treatment of multiple myeloma.,myelodysplastic syndromes (mds) - lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl) - lenalidomide is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - lenalidomide, quantity: 15 mg - capsule, hard - excipient ingredients: lactose; titanium dioxide; purified water; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm)- lenalidomide is indicated for treatment of multiple myeloma.,myelodysplastic syndromes (mds) - lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl) - lenalidomide is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - lenalidomide, quantity: 20 mg - capsule, hard - excipient ingredients: lactose; titanium dioxide; brilliant blue fcf; sunset yellow fcf; purified water; iron oxide yellow; gelatin; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm)- lenalidomide is indicated for treatment of multiple myeloma.,myelodysplastic syndromes (mds) - lenalidomide is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.,mantle cell lymphoma (mcl) - lenalidomide is indicated for the treatment of patients with relapsed and/or refractory mantle cell lymphoma.